Raymond T Chung MD

Gastroenterology•Boston, MA

Hepatology & Liver Transplantation

Professor of Medicine, Harvard Medical School, Director of Hepatology and Liver Center, Massachusetts General Hospital

Join to View Full Profile

55 Fruit Street Blk 4Gastroenterology AssociatesBoston, MA 02114
Phone+1 617-724-6006
Fax+1 617-724-6832

Summary

Dr. Raymond Chung is a gastroenterologist and hepatologist in Boston, MA and is Chief of Hepatology at Massachusetts General Hospital. He received his medical degree from Yale School of Medicine and has been in practice 31 years. He specializes in hepatology & liver transplantation and is experienced in hepatology.

Education & Training

Mass General Brigham/Massachusetts General HospitalFellowship, Gastroenterology, 1989 - 1993
Johns Hopkins UniversityResidency, Internal Medicine, 1986 - 1989
Yale School of MedicineClass of 1986

Certifications & Licensure

MA State Medical License 1989 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology
American Board of Internal Medicine Transplant Hepatology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2008, 2012-2014

Clinical Trials

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV) Start of enrollment: 2000 Nov 01
Completed
Phase 2
Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) Start of enrollment: 2004 Jul 01
Completed
Phase 2
Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus Start of enrollment: 2006 Feb 01
Completed
Phase 2
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients Start of enrollment: 2008 Mar 01
Completed
Phase 2
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B Start of enrollment: 2012 May 01
Terminated
Phase 3
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Start of enrollment: 2013 Apr 01
Withdrawn
Phase 4
HBV-HIV Coinfection Research Network Start of enrollment: 2014 Apr 01
Completed
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
Completed
Phase 1
Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant Start of enrollment: 2017 Feb 01
Completed
Phase 4
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C Start of enrollment: 2017 Feb 01
Completed
Phase 4
Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant Start of enrollment: 2018 Aug 01
Withdrawn
Phase 4
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant Start of enrollment: 2017 Nov 09
Terminated
Phase 4
HCV Post-Exposure Prophylaxis for Health Care Workers Start of enrollment: 2019 Aug 13
Withdrawn
Phase 4
Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant Start of enrollment: 2019 Feb 15
Withdrawn
Phase 4
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant Start of enrollment: 2019 Feb 05
Terminated
Phase 4
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients Start of enrollment: 2021 Jun 22
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Terlipressin-Associated Complete Heart Block.
Jiunn Song, Tristan Alfie, E Kevin Heist, Raymond T Chung
ACG Case Reports Journal. 2025-04-01
Prediagnostic Plasma Metabolites Are Associated with Incident Hepatocellular Carcinoma: A Prospective Analysis.
Robert M Wilechansky, Prasanna K Challa, Xijing Han, Xinwei Hua, Alisa K Manning
Cancer Prevention Research. 2025-04-01
Psychological Distress Is Prevalent and Interdependent Among Patients With Decompensated Cirrhosis and Their Caregivers.
Nneka N Ufere, Chengbo Zeng, John Donlan, Daniel Shalev, Alyson Kaplan
The American Journal of Gastroenterology. 2025-04-01

Journal Articles

Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-Infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study
Mandana Khalili, Mark Sulkowski, Marc G Ghany, Richard K Sterling, Raymond T Chung, David E Kleiner, Mamta K Jain, Nature
A Novel lncRNA Regulates HCV Infection Through IFI6
Raymond T Chung, Esperance A Schaefer, Hepatology
Serum Angiopoietin‐2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis
Andrew S Allegretti, Sagar U Nigwekar, Raymond T Chung, Sahir Kalim, Xavier Vela Parada, Ravi I Thadhani, Guillermo A Ortiz, Samir M Parikh, Hepatology
Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection
Ma Somsouk, Eoin R Feeney, Raymond T Chung, Steven Deeks, Annie J Kruger, Ricard Masia, Kathleen E Corey, Esperance A Schaefer, The Journal of Infectious Diseases
Join now to see all

Other

Investigational therapies for hepatitis C virus infection
Chung RT, Tai AW
http://www.uptodate.com/contents/investigational-therapies-for-hepatitis-c-virus-infection
UpToDate, Wolters Kluwer Health - 2013-04-05
Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1
Chung RT, Tai AW
http://www.uptodate.com/contents/studies-of-telaprevir-and-boceprevir-in-the-treatment-of-chronic-he
UpToDate, Wolters Kluwer Health - 2012-10-05

Authored Content

The Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score, Cardiovascular Risk Stratification and a Strategy for Secondary Prevention with EzetimibeMay 2018

Press Mentions

Could Statins Prevent Hepatocellular Carcinoma?April 1st, 2025
Statin Use Linked with Reduced Risks in Chronic Liver DiseaseMarch 17th, 2025
Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver DiseaseMarch 17th, 2025
Join now to see all

Grant Support

Discovery And Assessment Of Genetic Determinants Of HCV And HIV ControlNational Institute On Drug Abuse2011
Research Training In Digestive DiseasesNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
The Central Role Of The Hepatocyte In HCV PersistenceNational Institute Of Allergy And Infectious Diseases2009–2011
Pilot/Feasibility Studies Program Of The HCV Persistence Study Group (HPSG)National Institute Of Allergy And Infectious Diseases2009–2011
Mechanisms Of Immune Failure In Chronic Infection: Hepatitis C As A Key ParadigmNational Institute Of Allergy And Infectious Diseases2009–2011
Administrative Core For The HCV Persistence Study Group (HPSG)National Institute Of Allergy And Infectious Diseases2009–2011
Harvard Hepatitis B ConsortiumNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
Patient-Oriented Research On Hepatitis In Special PopulationsNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2011
Discovery And Assessment Of Genetic Determinants Of HCV And HIV ControlNational Institute Of Allergy And Infectious Diseases2010
Serum Apoptosis Markers As Biomarkers In Acute Liver FailureNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
Hiv-Hepatitis C Virus Interactions And PathogenesisNational Institute Of Allergy And Infectious Diseases2006–2010
Chemical Genetics:Cellular Regulators Of HCV (RMI)National Institute Of Neurological Disorders And Stroke2004
Novel Animal Models Of Hcv-Related HepatocarcinogenesisNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2003
Hepatitis C Virus-Specific ReplicaseNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1998

Raymond T Chung MD

Dr. Chung is on Doximity

Summary

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Authored Content

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.